SimonMed Imaging has selected Korea-based Lunit’s AI-powered breast cancer detection platform to support screenings at more than 170 centers across the U.S., the companies said Wednesday. 

The U.S.-based outpatient imaging provider will integrate Lunit INSIGHT DBT and Volpara Analytics into its Personalized Breast Cancer Detection (PBCD) program following what it called an “extensive evaluation” of AI solutions currently on the market.

Lunit INSIGHT DBT is a deep learning-based software designed to assist radiologists by analyzing 3D mammograms—also known as digital breast tomosynthesis (DBT)—to identify subtle signs of cancer that may be missed in traditional reads. Volpara Analytics, meanwhile, provides real-time quality assurance by monitoring imaging performance and helping standardize breast cancer screening across sites.

"This is the most advanced AI solution we’ve ever adopted,” said John Simon, founder and CEO of SimonMed Imaging. 

“This is more than just an upgrade—it’s an important step forward for our patient’s health,” added Dr. Sean Raj, chief innovation officer at SimonMed Imaging and a Fellow of the Society of Breast Imaging. “We’ve evaluated a range of AI technologies, and Lunit’s performance, speed, and clinical validation stood above the rest.”

Trained on millions of mammograms, Lunit INSIGHT DBT is designed to enhance sensitivity (the ability to catch cancers) and specificity (the ability to avoid false positives). SimonMed said the software will be rolled out across its national network, which includes over 200 subspecialty-trained radiologists, to support faster reads and improve patient outcomes.

With Volpara and Lunit, SimonMed is helping set a new standard for what modern high-quality breast screening should look like: data-driven, patient-focused, and grounded in clinical excellence, said Volpara CEO Craig Hadfield. 

“SimonMed's selection of Lunit is a strong signal that AI has moved beyond proof of concept and is now powering critical decisions in frontline care," said Brandon Suh, CEO of Lunit. "This partnership represents the kind of strategic alignment that accelerates innovation - bringing together leading technology, clinical expertise, and a shared mission to improve outcomes for every patient."